A Patient with High Cardiometabolic Risk

  • Alpana ShuklaEmail author
  • Lindsay Mandel


A 30-year-old South Asian male presents for an annual health exam. He denies any specific systemic complaints but admits to feeling somewhat run down lately, which he attributes to his work stress. Although never considered overweight, he has gained 5–6 lb over the past year, which came to his attention when his pants size increased. He has no significant past medical history. He has a positive family history for type 2 diabetes in his father and paternal grandfather, and premature coronary artery disease in his father, who had a CABG for triple vessel disease at the age of 50. He doesn’t smoke and consumes four to five alcoholic drinks per week. He is lacto-ovo vegetarian and his diet is heavy on carbohydrates. He has cereal for breakfast; a sandwich, pizza, or pasta for lunch; and a traditional, Indian meal at night which includes half a plate of rice. He does not do structured exercise besides walking. On examination, his weight is 168 lb, BMI 24.8 kg/m2, waist circumference 93 cm, and BP 126/80 mmHg. He has acanthosis nigricans around his neck. Systemic exam is within normal limits. Laboratory data show the following abnormalities: FBS 105, HbA1c 6.2%, triglycerides 200 mg/dl, HDL 36 mg/dl, and hsCRP 3 mg/dl.


Cardiometabolic risk Prediabetes Dyslipidemia Metformin HDL cholesterol 


  1. 1.
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRefGoogle Scholar
  2. 2.
    Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–9.CrossRefGoogle Scholar
  3. 3.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.CrossRefGoogle Scholar
  4. 4.
    International Diabetes Federation. The IDF consensus worldwide definition of metabolic syndrome. Brussels. 2006.Google Scholar
  5. 5.
    Westphal SA. Obesity, abdominal obesity, and insulin resistance. Clin Cornerstone. 2008;9(1):23–9. discussion 30–31CrossRefGoogle Scholar
  6. 6.
    Price GM, Uauy R, Breeze E, Bulpitt CJ, Fletcher AE. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am J Clin Nutr. 2006;84(2):449–60.CrossRefGoogle Scholar
  7. 7.
    World Health Organization. Report of a WHO expert consultation. Waist circumference and waist-hip ratio. Geneva, Switzerland: 2008.Google Scholar
  8. 8.
    Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore R, Pepys MB, Kooner JS. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. 2001;104:145–15.CrossRefGoogle Scholar
  9. 9.
    Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein in body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25:1327–31.CrossRefGoogle Scholar
  10. 10.
    Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004;24:1509–15.CrossRefGoogle Scholar
  11. 11.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, and Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefGoogle Scholar
  12. 12.
    Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. Indian Diabetes Prevention Programme (IDPP).The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.CrossRefGoogle Scholar
  13. 13.
    Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008;371:1783–9.CrossRefGoogle Scholar
  14. 14.
    Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish diabetes prevention study group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet. 2006;368:1673–9.CrossRefGoogle Scholar
  15. 15.
    Knowler WC, Fowler SE, Hamman RF, et al. Diabetes prevention program research group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677–86.CrossRefGoogle Scholar
  16. 16.
    Nathan DM, Barrett-Connor E, Crandall JP, et al. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications: the DPP outcomes study. Lancet Diabetes Endocrinol. 2015;3:866–75.CrossRefGoogle Scholar
  17. 17.
    Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRefGoogle Scholar
  18. 18.
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.CrossRefGoogle Scholar
  19. 19.
    le Roux CW, Astrup A, Fujioka K, et al. SCALE obesity prediabetes NN8022-1839 study group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–409.CrossRefGoogle Scholar
  20. 20.
    Gerstein HC, Yusuf S, Bosch J, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.CrossRefGoogle Scholar
  21. 21.
    DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW study. pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.CrossRefGoogle Scholar
  22. 22.
    Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35:731–7.CrossRefGoogle Scholar
  23. 23.
    American Diabetes Association Standards of Medical Care in Diabetes-2018. Prevention or delay of type 2 diabetes. Diabetes Care. 2018;41(Supplement 1):S51–4.CrossRefGoogle Scholar
  24. 24.
    Fedewa MV, Gist NH, Evans EM, Dishman RK. Exercise and insulin resistance in youth: a meta-analysis. Pediatrics. 2014;133:e163–74.CrossRefGoogle Scholar
  25. 25.
    Thorp AA, Kingwell BA, Sethi P, Hammond L, Owen N, Dunstan DW. Alternating bouts of sitting and standing attenuate postprandial glucose responses. Med Sci Sports Exerc. 2014;46:2053–61.CrossRefGoogle Scholar
  26. 26.
    Shukla AP, Andono J, Touhamy SH, et al. Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes. BMJ Open Diabetes Research and Care. 2017;5:e000440. Scholar
  27. 27.
    Imai S, Fukui M, Kajiyama S. Effect of eating vegetables before carbohydrates on glucose excursions in patients with type 2 diabetes. J Clin Biochem Nutr. 2014;54(1):7–11.CrossRefGoogle Scholar
  28. 28.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and MetabolismWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations